Lebrikizumab, a humanized monoclonal antibody targeting IL-13, was previously shown to improve asthma symptoms particularly in patients with a high serum IgE level, high blood eosinophil counts, and an increased expression of interleukin-13–related genes in the lung [204]. The gene discussed is IL13; the disease is asthma.